Bearish
Summit Therapeutics (NASDAQ: SMMT) posts larger Q1 loss amid cash burn and trials
Summit Therapeutics (NASDAQ: SMMT) reported a significantly larger net loss of $189.4 million in Q1 2026, compared to $62.9 million in the prior year,...